香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司2025年年度報 告摘要》《康希諾生物股份公司2025年年度報告》《康希諾生物股份公司第三屆董 事會第十次會議決議公告》《康希諾生物股份公司關於2025年度利潤分配方案的 公告》《康希諾生物股份公司關於續聘會計師事務所的公告》《康希諾生物股份公 司關於提請股東會授權董事會以簡易程序向特定對象發行股票的公告》《康希諾 生物股份公司關於2026年度對外擔保預計的公告》《康希諾生物股份公司2025年 ...

Group 1: Nvidia Market Reaction - Nvidia's market value dropped by $259.2 billion (approximately 1.77 trillion RMB), marking the largest single-day decline since April 16 of the previous year, with a decrease of over 5% in stock price [1] - This decline occurred despite Nvidia reporting better-than-expected earnings, indicating that the market is looking for answers beyond just chip sales [1] Group 2: Leadership Changes at Ningbo Bank - Ningbo Bank announced significant management changes, electing Zhuang Lingjun as the new chairman and appointing Feng Peijiong as the new president, both of whom are in their 40s [3] - This transition marks the end of Lu Huayu's over 20-year leadership, and Zhuang Lingjun will become the youngest chairman among A-share listed banks [3] Group 3: Macro Economic Developments - The Chinese Ministry of Commerce confirmed ongoing communication with the U.S. regarding the sixth round of economic and trade consultations, emphasizing a commitment to maintaining stable and sustainable economic relations [5] - The People's Bank of China issued a notice supporting domestic banks in conducting cross-border RMB interbank financing, linking financing balances to capital levels and market conditions [6] Group 4: Regulatory Changes in Food Safety - New regulations for online food delivery services will take effect on June 1, requiring platforms to take responsibility for food safety throughout the entire operational process [8] - The regulations mandate that food delivery platforms must ensure compliance and quality, moving beyond merely collecting commissions [8] Group 5: AI Model Usage in China - For the first time, the volume of API calls for Chinese AI models surpassed that of U.S. models, with Chinese models reaching 41.2 trillion tokens compared to 29.4 trillion tokens from the U.S. [10] - Four out of the top five AI models globally are from Chinese companies, contributing 85.7% of the total calls [10] Group 6: Real Estate Market Trends - In January, the average price of second-hand residential properties in 100 cities fell by 0.85% month-on-month, while new home prices in cities like Chengdu and Shanghai saw a structural increase, rising by 0.18% month-on-month [13] - The average rental price in 50 cities decreased by 0.45% month-on-month, continuing a trend of seasonal decline [13] Group 7: Corporate Financial Performance - Tianhe Energy reported a significant loss of 6.994 billion RMB for 2025, with total revenue decreasing by 16.20% year-on-year [21] - Hubei Hongyu New Materials achieved a net profit of 18.43 million RMB for 2025, marking a 396.55% increase year-on-year [22] - NIO's chip subsidiary signed a financing agreement exceeding 2.2 billion RMB, aimed at supporting the development of competitive chip products [24] - Luckin Coffee reported a net profit of 3.6 billion RMB for 2025, with a revenue increase of 43.0% year-on-year [28] - Juchip Technology achieved a net profit of 205 million RMB for 2025, reflecting a 91.95% increase year-on-year [29]

Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, achieving a total revenue of approximately 1.068 billion yuan, marking a year-on-year growth of 26.18%, and successfully turning a profit with a net profit of approximately 27.87 million yuan, compared to a loss in the previous year [1] Financial Performance - Total revenue for the period reached approximately 1.068 billion yuan, reflecting a year-on-year increase of 26.18% [1] - The net profit attributable to the parent company was approximately 27.87 million yuan, indicating a turnaround from a loss in the previous year [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with a focus on the growth of its first quadrivalent meningococcal vaccine, Manhaixin® [1] - Cost reduction and efficiency improvement measures have been effectively executed, leading to better expense management [1] Operational Efficiency - The company has optimized production and sales coordination, resulting in an improvement in gross profit margin [1] - Overall profitability has significantly increased, with the company successfully achieving a positive net profit for the reporting period [1]

Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, with total revenue increasing by 26.18% year-on-year and achieving a net profit attributable to shareholders for the first time [1][2] Financial Performance - Total revenue reached 1.068 billion RMB, marking a year-on-year growth of 26.18% [1] - The net profit attributable to shareholders was 27.8727 million RMB, indicating a turnaround from a loss to profit [1][2] - Basic earnings per share were reported at 0.11 RMB [1] Operational Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to effective expense management [1][2] - The gross profit margin improved due to optimized production and sales coordination [1] Research and Development - The company continued to advance its R&D projects and international collaborations, receiving government grants and international R&D funding [1] - Non-recurring income related to these grants was recognized during the reporting period [1] Share Capital - The company's share capital was approximately 247 million shares at the end of the reporting period, a decrease of about 410,000 shares due to the cancellation of previously repurchased A-shares [2]

Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, with total revenue reaching 1.068 billion RMB, marking a year-on-year growth of 26.18% and a return to profitability with a net profit of 27.87 million RMB [1][2] Financial Performance - Total revenue for the reporting period was 1.068 billion RMB, reflecting a year-on-year increase of 26.18% [1][2] - The net profit attributable to the parent company was 27.87 million RMB, indicating a turnaround from a loss to profit [1][2] - Basic earnings per share were reported at 0.11 RMB, with the weighted average return on equity turning positive [2] Operational Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to significant savings in various expenses [2] - Resource allocation was optimized, contributing to improved operational efficiency during the reporting period [2] Product Development and Support - The company continued to focus on innovation and commercialization, with the growth of its first quadrivalent meningococcal vaccine, Manhaixin® [1] - The company received government grants and international research funding, which contributed to non-recurring income during the reporting period [1]

Core Viewpoint - The company, CanSino (688185.SH), reported a significant turnaround in its financial performance for the fiscal year 2025, achieving a total revenue of 1.068 billion yuan, marking a year-on-year growth of 26.18% and a net profit attributable to shareholders of 27.87 million yuan, compared to a loss of 379 million yuan in the previous year [2]. Financial Performance - Total revenue for 2025 reached 1.068 billion yuan, reflecting a 26.18% increase year-on-year [2]. - The net profit attributable to shareholders was 27.87 million yuan, a significant recovery from a loss of 379 million yuan in the same period last year [2]. Product Performance - The revenue from the company's first quadrivalent meningococcal vaccine, Manhaixin®, continued to grow steadily during the reporting period [2]. Research and Development - The company has accelerated its R&D projects and international collaborations, which have contributed to its financial performance [2]. - CanSino received government special subsidies and international research funding, which were recognized as non-recurring gains during the reporting period [2].

Core Viewpoint - The company reported a significant improvement in its financial performance for the fiscal year 2025, achieving a total revenue of approximately 1.068 billion yuan, marking a year-on-year growth of 26.18% [1] Financial Performance - The net profit attributable to the parent company's owners was approximately 27.87 million yuan, indicating a turnaround from a loss to profit compared to the same period last year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately -92.50 million yuan [1] Strategic Initiatives - The company continues to focus on innovation and commercialization as key components of its development strategy, with the revenue from its first quadrivalent meningococcal vaccine, Manhaixin®, showing sustained growth [1] - Cost reduction and efficiency improvement measures have been effectively implemented, leading to better expense management [1] - The optimization of production and sales coordination has contributed to an increase in gross profit margin [1] Research and Development - The company is advancing its R&D projects rapidly and has engaged in international collaborations, receiving government special subsidies and international research funding [1] - The recognition of related non-recurring income during the reporting period reflects the support received for its R&D efforts [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for the expanded age range of its meningococcal polysaccharide conjugate vaccine, MCV4, from children aged 3 months to 3 years to children aged 3 months to 6 years [1] Group 1: Company Developments - The approval allows the company's product, MCV4 (marketed as Manhaixin®), to be administered to a broader age group, enhancing its market potential [1] - Manhaixin® is the first quadrivalent meningococcal conjugate vaccine in China, addressing the gap in high-end vaccines in the country [1] - The innovative advantages of Manhaixin® have led to a strong market performance, with a continuous increase in market share [1] Group 2: Industry Impact - The introduction of Manhaixin® helps to reduce the gap between China and developed countries in the field of meningococcal vaccines [1] - The vaccine provides a better solution for the prevention of meningococcal disease in children aged 6 years and below in China [1]

Core Viewpoint - Company has received approval from the National Medical Products Administration for the expanded age range of its meningococcal polysaccharide conjugate vaccine, MCV4, from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children" [1] Group 1 - The product, known as Manhaixin®, is China's first quadrivalent meningococcal conjugate vaccine, which helps bridge the gap in this field between China and developed countries [1] - The approval fills a significant gap in the availability of high-end vaccines in China, providing a better solution for the prevention of meningococcal disease in children aged 6 years and below [1] - Manhaixin® has demonstrated strong market performance and an increasing market share due to its innovative advantages [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for an expanded age range for its meningococcal polysaccharide conjugate vaccine, MCV4, from children aged 3 months to 3 years to children aged 3 months to 6 years [1] Group 1 - The approval allows the company's product, MCV4 (marketed as Manhaixin®), to be administered to a broader age group, enhancing its market potential [1] - Manhaixin® is the first quadrivalent meningococcal conjugate vaccine in China, addressing the gap in high-end vaccines in the country and reducing the disparity with developed nations [1] - The vaccine provides a superior solution for the prevention of meningococcal disease in children aged 6 years and below, showcasing strong market performance and increasing market share [1]